Whereas some reports suggest that immunoreactive serum IL-33 is a biomarker for a favorable tumor prognosis (50, 51), other studies outline its pro-tumorigenic role, particularly its effects on anti-tumor immunity. This evidence concerns the gene IL33 and neoplasm.